These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17268528)

  • 1. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
    Baldwin BR; Li L; Tse KF; Small S; Collector M; Whartenby KA; Sharkis SJ; Racke F; Huso D; Small D
    Leukemia; 2007 Apr; 21(4):764-71. PubMed ID: 17268528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.
    Vu HA; Xinh PT; Masuda M; Motoji T; Toyoda A; Sakaki Y; Tokunaga K; Sato Y
    Leukemia; 2006 Aug; 20(8):1414-21. PubMed ID: 16761019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
    Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
    Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
    Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
    Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells.
    Broxmeyer HE; Lu L; Cooper S; Ruggieri L; Li ZH; Lyman SD
    Exp Hematol; 1995 Sep; 23(10):1121-9. PubMed ID: 7544740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
    Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
    Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
    Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
    Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.
    Tse KF; Mukherjee G; Small D
    Leukemia; 2000 Oct; 14(10):1766-76. PubMed ID: 11021752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internal tandem duplication of Flt3 modulates chemotaxis and survival of hematopoietic cells by SDF1alpha but negatively regulates marrow homing in vivo.
    Fukuda S; Pelus LM
    Exp Hematol; 2006 Aug; 34(8):1041-51. PubMed ID: 16863910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.
    D'Andrea RJ; Harrison-Findik D; Butcher CM; Finnie J; Blumbergs P; Bartley P; McCormack M; Jones K; Rowland R; Gonda TJ; Vadas MA
    J Clin Invest; 1998 Dec; 102(11):1951-60. PubMed ID: 9835620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TEL-JAK2 transgenic mice develop T-cell leukemia.
    Carron C; Cormier F; Janin A; Lacronique V; Giovannini M; Daniel MT; Bernard O; Ghysdael J
    Blood; 2000 Jun; 95(12):3891-9. PubMed ID: 10845925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia.
    Cadieux C; Fournier S; Peterson AC; Bédard C; Bedell BJ; Nepveu A
    Cancer Res; 2006 Oct; 66(19):9492-501. PubMed ID: 17018605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.